Humacyte (HUMA) 10-Q2023 Q2 Quarterly report

Filed: 14 Aug 23, 8:44am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: arrangement, assure, authoritative, bifurcated, bifurcation, bore, Cap, compound, decline, diminished, disposal, Disposition, embedded, exceed, expansion, favorable, forecast, forecasted, impute, Licnse, methodology, outlined, payoff, pending, point, primary, proportionate, rank, refundable, release, resolved, retention, strength, thousand, timeline, unaccreted, unamortized, Vessel

Removed: accretion, bear, begin, Bioartificial, coating, collateralized, combined, present, shutdown, sum, variable

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated HUMA transcripts

HUMA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

In connection with the Quarterly Report on Form 10-Q of Humacyte, Inc. (the “Company”) for the quarter ended June 30, 2023 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Laura E. Niklason, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 14, 2023	By:	/s/ Laura E. Niklason
		Name:	Laura E. Niklason, M.D., Ph.D.
		Title:	President and Chief Executive Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.